Literature DB >> 485583

Behaviour of effector cells, synovial fluids, and sera from rheumatoid arthritis patients in antibody-dependent cell-mediated cytotoxicity.

L A Cooke, F C Hay, R Perumal.   

Abstract

Antibody-dependent cell-mediated cytotoxicity (ADCC) was examined in patients with rheumatoid arthritis (RA). The cytotoxicity of peripheral blood leucocytes from patients with RA was similar to that found in normal persons, whereas ADCC was less effective in RA synovial fluid cells. It is possible that the activity in these cells is lower because of immune complexes and other factors being absorbed from the synovial fluid itself. Although patients' sera had little effect on normal peripheral blood leucocytes, synovial fluid from RA patients was markedly inhibitory in ADCC. The degree of inhibition correlated significantly with the clinical status of the patients.

Entities:  

Mesh:

Year:  1979        PMID: 485583      PMCID: PMC1000447          DOI: 10.1136/ard.38.3.252

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  15 in total

1.  Antibody-dependent cell-mediated cytotoxicity in selected autoimmune diseases.

Authors:  J L Feldmann; M J Becker; H Moutsopoulos; K Fye; M Blackman; W V Epstein; N Talal
Journal:  J Clin Invest       Date:  1976-07       Impact factor: 14.808

2.  Antibody in the induction and inhibition of lymphocyte cytotoxicity.

Authors:  I C MacLennan
Journal:  Transplant Rev       Date:  1972

3.  Lymphocyte mediated cytotoxicity in vitro. Induction and inhibition by humoral antibody and nature of effector cells.

Authors:  P Perlmann; H Perlmann; H Wigzell
Journal:  Transplant Rev       Date:  1972

4.  Modulation of polymorphonuclear leukocyte-mediated antibody-dependent cellular cytotoxicity.

Authors:  R P Gale; J Zighelboim
Journal:  J Immunol       Date:  1974-12       Impact factor: 5.422

5.  Presence of aggregated gamma-G-globulin in certain rheumatoid synovial effusions.

Authors:  K Hannestad
Journal:  Clin Exp Immunol       Date:  1967-07       Impact factor: 4.330

Review 6.  Cytotoxic effects of lymphoid cells in vitro.

Authors:  P Perlmann; G Holm
Journal:  Adv Immunol       Date:  1969       Impact factor: 3.543

7.  The role of immunoglobulins in lymphocyte-mediated cell damage, in vitro. I. Comparison of the effects of target cell specific antibody and normal serum factors on cellular damage by immune and non-immune lymphocytes.

Authors:  I C MacLennan; G Loewi; B Harding
Journal:  Immunology       Date:  1970-03       Impact factor: 7.397

8.  Inhibition of spontaneous and antibody-dependent cellular cytotoxicity by sera and isolated antiglobulin preparations from rheumatoid arthritis patients.

Authors:  P C Fink; I Schedel; H H Peter; H Deicher
Journal:  Scand J Immunol       Date:  1977       Impact factor: 3.487

9.  Antibody-dependent human lymphocytotoxicity: a micro assay system.

Authors:  W P Zeijlemaker; M T Roos; P T Schellekens; V P Eijsvoogel
Journal:  Eur J Immunol       Date:  1975-08       Impact factor: 5.532

10.  Antibody-dependent cell-mediated cytotoxicity: heterogeneity of effector cells in human peripheral blood.

Authors:  H R MacDonald; G D Bonnard; B Sordat; S A Zawodnik
Journal:  Scand J Immunol       Date:  1975-09       Impact factor: 3.487

View more
  3 in total

1.  Antibody-dependent cellular cytotoxicity in recurrent aphthous ulceration.

Authors:  J S Greenspan; N Gadol; J A Olson; N Talal
Journal:  Clin Exp Immunol       Date:  1981-06       Impact factor: 4.330

2.  Immunological studies in patients with rheumatoid arthritis receiving azathioprine and myocrisin in combination.

Authors:  P Lewis; B L Hazleman; J R Park; D Y Bulgen; D Franks; C Hurd; D L Brown
Journal:  Clin Rheumatol       Date:  1982-09       Impact factor: 2.980

3.  Antibody dependent cell-mediated cytotoxicity in different forms of rheumatoid arthritis patients.

Authors:  B Misiewicz-Poltorak; M Plachecka-Gutowska
Journal:  Clin Rheumatol       Date:  1984-09       Impact factor: 2.980

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.